PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.\', \'Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.\', \'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.\', \'Department of Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.\', \'Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/onco.13719
?:doi
?:hasPublicationType
?:journal
  • The oncologist
is ?:pmid of
?:pmid
?:pmid
  • 33586274
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all